Disposal of Expired, Degraded and Obsolete Devices in Nigeria under NAFDAC Supervision

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Nigeria’s requirements for the disposal of expired, degraded or obsolete devices are set out in Article 13: registration certificate holders and users must dispose of them in accordance with the provisions of the competent authority and under NAFDAC supervision.

Three phrases determine how hard this provision is to execute: holders and users (dual duty holders), in accordance with the provisions of the competent authority (the rules sit elsewhere), and under NAFDAC supervision (not self-directed destruction). Together they mean that disposal is a documented, witnessed and verifiable procedure with official involvement at its centre — never a quietly arranged trip to an incinerator.

2. Legal basis

RegulationReference numberPublication dateProvisions
NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024S.I. No. 42 of 202416 October 2024Article 13 (disposal of expired, degraded and obsolete devices), Article 17 (expiry date labelling), Article 12(2) (the react element of PMS)
NAFDAC Recall of Defective Medical ProductsPMS-GDL-020-00Effective 30 September 2024§4–§6 (grading, communication, progress monitoring)
NAFDAC Medical Devices GMP Guidelines 2024DER-GDL-025-00Effective 11 November 2024§11.3–§11.4 (nonconforming product control), §13.1(f) (complaint record retention period)
NAFDAC Medical Devices, including In-vitro Diagnostics and Related Products Regulations, 2025 (draft)None (draft, not gazetted)Published 23 July 2025Part 8 (vigilance), §79–§90 (storage and distribution, draft)

3. Expert insights

Insight one: the duty holders under Article 13 are the holder and the user.

Like Article 12(3) (manufacturers and importers), Article 13 uses a conjunctive construction — both the registration certificate holder and the user are responsible. For foreign manufacturers, this means hospitals, clinics and laboratories as end users also carry a statutory disposal obligation, and their practical capability is often limited. The value of the authorised representative lies precisely in taking over this obligation and making it a process. A structured programme of collection, storage and supervised destruction, funded by the manufacturer and executed locally, is the only realistic way to make the obligation real.

Insight two: three states — expired, degraded, obsolete — correspond to three trigger scenarios.

Expiry is read against the expiry date on the label (Article 17); degradation is detected when storage conditions fail (Articles 11 and 22); obsolescence may result from technology iteration or from changes in registration status (suspension or cancellation under Article 8). The identification mechanisms for the three states differ: expiry is tracked through a shelf-life register, degradation through storage monitoring and complaint surveillance, and obsolescence through product and registration status management. A disposal programme that only watches expiry dates will miss the other two states entirely.

Insight three: under NAFDAC supervision means you cannot destroy on your own.

Article 13 requires disposal to be carried out under NAFDAC supervision. The practical meaning: declare before destruction, make the process verifiable, and obtain evidence afterwards. Sending material to a landfill or incinerator unilaterally, however proper the actual operation, fails Article 13 for lack of the supervision element. The declaration should identify the items, quantities, batch numbers and the proposed method, so the agency can schedule or witness the event.

Insight four: disposal and recall are triggered together; write the plans together.

A recall typically generates three categories of material awaiting disposal at the same time: recalled defective products, expired stock, and degraded stock. The disposal plan should therefore be prepared as one document with the recall plan, sharing a single set of procedures for reconciliation, quarantine, declaration, destruction and evidence retention. Keeping them separate creates the gap where the recall is completed but the disposal has no evidence. Auditors and inspectors read these documents side by side, and inconsistency between them is a finding in itself.

Insight five: the GMP nonconforming product provisions are the internal basis; Article 13 is the external procedure.

DER-GDL-025-00 §11.3–§11.4 govern the identification, quarantine and disposal records of nonconforming product (internal); Article 13 governs final disposal under official supervision (external). Quarantine and register internally first, then proceed to supervised destruction externally — this is the only compliant sequence. Reversing it, for instance by destroying material before it is ever recorded, produces evidence trails that cannot support either system.

4. Practical recommendations

  1. Prepare the disposal plan as one document with the recall plan, sharing reconciliation, quarantine, declaration, destruction and evidence procedures.
  2. Assign the Article 13 obligations explicitly in the authorised representative agreement, covering coordination with end users.
  3. Establish identification mechanisms for the three states: a shelf-life register (expiry), storage and complaint monitoring (degradation), product and registration status management (obsolescence).
  4. Declare before destruction, retain evidence during, and obtain certificates afterwards, forming a complete closed loop of documentation.
  5. Quarantine and register internal nonconforming product under GMP §11.3–§11.4 first, then run the external supervised procedure.
  6. Align the disposal record retention period with complaint records (GMP §13.1(f): not less than 1 year after expiry, or 1 year after complaint resolution, whichever is longer).

5. Verification checklist

  • □ The disposal plan has been prepared jointly with the recall plan (Article 13).
  • □ The authorised representative agreement assigns the Article 13 obligations and end-user coordination.
  • □ Each of the three states — expired, degraded, obsolete — has an identification mechanism and register.
  • □ The destruction process contains declaration, in-process evidence and post-event certification (under NAFDAC supervision).
  • □ Internal nonconforming product has been quarantined and registered under GMP §11.3–§11.4.
  • □ The disposal record retention period complies with GMP §13.1(f).

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC Regulations text (S.I. No. 42 of 2024, Articles 11, 12(2), 13, 17, 22), the recall guideline (PMS-GDL-020-00, effective 30 September 2024) and the GMP Guidelines (DER-GDL-025-00 §11.3–§11.4, §13.1(f)); the specific content of the competent authority provisions is subject to the current text of that authority. Its original documents were not obtained in this round, so those elements are treated as a practical estimate.

  • Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
  • Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail